Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Loss of Central Nervous System Component of Dopaminergic Inhibition of Prolactin Secretion in Patients with Prolactin-Secreting Pituitary Tumors
Stuart A. Fine, Lawrence A. Frohman
Stuart A. Fine, Lawrence A. Frohman
Published April 1, 1978
Citation Information: J Clin Invest. 1978;61(4):973-980. https://doi.org/10.1172/JCI109022.
View: Text | PDF
Research Article

Loss of Central Nervous System Component of Dopaminergic Inhibition of Prolactin Secretion in Patients with Prolactin-Secreting Pituitary Tumors

  • Text
  • PDF
Abstract

The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. To distinguish between these effects, 10 normal subjects (6 male, 4 female) and 8 patients with hyperprolactinemia associated with pituitary tumors were given l-dopa, 0.5 g alone, or 0.1 g after a 24-h pretreatment with carbidopa, 50 mg every 6 h, which produces peripheral dopa decarboxylase inhibition. Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13±2 ng/ml) after l-dopa alone (48±4%) and after l-dopa plus carbidopa (58±6%). In patients with pituitary tumors and elevated plasma PRL (73±14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47±6%). However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19±4%) which was significantly less than after l-dopa alone (P < 0.001). Urinary homovanillic acid excretion, which reflected peripheral dopa decarboxylation was similar in controls and tumor patients after l-dopa both alone and after carbidopa pretreatment. Comparable suppression of PRL levels in response to a dopamine infusion (4 μg/kg per min for 3 h) was observed in controls and tumor patients. The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. In contrast, patients with tumors, while retaining peripheral dopaminergic inhibitory effects on PRL secretion, exhibit a marked reduction of central dopaminergic inhibition of PRL secretion.

Authors

Stuart A. Fine, Lawrence A. Frohman

×

Total citations by year

Year: 2021 2020 2018 2017 2011 2009 2008 2005 2002 1999 1998 1997 1995 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 1980 1979 1977 Total
Citations: 1 1 1 1 2 2 1 1 1 1 2 1 1 1 1 3 2 4 2 9 7 8 8 9 5 2 1 78
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (78)

Title and authors Publication Year
Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology
S Fanti, G Gnanasegaran, I Carrió
2021
The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-β1 signaling in rats
L Ren, W Liu, C Wang, Y Yang, X Huang, C Wang, Y Li
Journal of Ethnopharmacology 2020
18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma:
C Heimburger, C Bund, P Addeo, B Goichot, A Imperiale
Clinical Nuclear Medicine 2018
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms
Y Wei, L La, L Wang, R Batey, C Wang, Y Li
Journal of Ethnopharmacology 2017
The renin-angiotensin-aldosterone axis in patients with tumoral hyperprolactinemia
P Mediskou, MP Yavropoulou, K Kotsa, X Tsekmekidou, A Psarakou-Gotzamani, A Papazisi, A Chlorou, JG Yovos
Clinical Endocrinology 2011
Prolactin
MP Gillam, ME Molitch
The Pituitary 2011
Yen & Jaffe's Reproductive Endocrinology
RA Lobo
Yen & Jaffe's Reproductive Endocrinology 2009
Yen & Jaffe's Reproductive Endocrinology
SF Thung, ER Norwitz
Yen & Jaffe's Reproductive Endocrinology 2009
Diagnosis and Management of Pituitary Disorders
B Swearingen, BM Biller
2008
Persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of long term use of estrogen: are the tuberoinfundibular dopaminergic neurons permanently lesioned?
LA Casulari, F Celotti, LA Naves, L Domingues, C Papadia
Arquivos brasileiros de endocrinologia e metabologia 2005
Prolactinomas: Aspectos neurocirúrgicos
OI Tella, MA Herculano, R Delcello, PH Aguiar
Arquivos de Neuro-Psiquiatria 2002
MEDICAL TREATMENT OF PROLACTINOMAS
ME Molitch
Endocrinology and metabolism clinics of North America 1999
Tamoxifen Inhibits GH3 Cell Growth in Culture via Enhancement of Apoptosis
SY Lee, BT Ahn, SH Baik, BL Lee
Neurosurgery 1998
Current Techniques in Neurosurgery
M Salcman
1998
Advances and Technical Standards in Neurosurgery
F Cohadon, VV Dolenc, JL Antunes, H Nornes, JD Pickard, HJ Reulen, AJ Strong, N de Tribolet, CA Tulleken
Advances and technical standards in neurosurgery 1997
Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia
F Larrea, JL Sandoval, E Salinas, VA Franco-Rodriguez, I Méndez, A Ulloa-Aguirre
Clinical Endocrinology 1995
Dopamine, the dopamine D2 receptor and pituitary tumours
DF Wood, JM Johnston, DG Johnston
Clinical Endocrinology 1991
LONG-TERM FOLLOW-UP OF‘CURED’PROLACTINOMA PATIENTS AFTER SUCCESSFUL ADENOMECTOMY
E Ciccarelli, E Ghigo, C Miola, G Gandini, EE Muller, F Camanni
Clinical Endocrinology 1990
Defective natural killer cell activity in puerperal hyperprolactinemia
I Nicoletti, R Gerli, S Orlandi, G Migliorati, P Rambotti, C Riccardi
Journal of Reproductive Immunology 1989
Hyperprolactinemia: neuroendocrine and diagnostic aspects
F Camanni, E Ciccarelli, E Ghigo, EE Müller
Journal of Endocrinological Investigation 1989
Effect of neuroleptic withdrawal on plasma prolactin: A possible marker of receptor adaptation
B Kirkpatrick, RW Buchanan, K Maeda, WT Carpenter, D Jauch, CA Tamminga
Biological Psychiatry 1989
Suprasellar craniopharyngioma associated with hyperprolactinemia, pituitary lactotroph hyperplasia, and microprolactinoma
MD Cusimano, K Kovacs, JM Bilbao, WS Tucker, W Singer
Journal of Neurosurgery 1988
Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases:
KY Ho, MO Thorner
Drugs 1988
Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia
R Gerli, C Riccardi, I Nicoletti, S Orlandi, C Cernetti, F Spinozzi, P Rambotti
Journal of Clinical Immunology 1987
Pathogenesis of Pituitary Tumors
ME Molitch
Endocrinology and metabolism clinics of North America 1987
The Pituitary Gland
CR Kannan
1987
Current Concepts and Treatment of Hyperprolactinemia
DF Archer
Obstetrics and Gynecology Clinics of North America 1987
THE PREOPERATIVE AND POSTOPERATIVE INVESTIGATION OF TSH AND PROLACTIN RELEASE IN THE MANAGEMENT OF PATIENTS WITH HYPERPROLACTINAEMIA DUE TO PROLACTINOMAS AND NONFUNCTIONAL PITUITARY TUMOURS: RELATIONSHIP TO ADENOMA SIZE AT SURGERY
MF Scanlon, JR Peters, J Salvador, SH Richards, R John, S Howell, ED Williams, JP Thomas, R Hall
Clinical Endocrinology 1986
Reduced number of natural killer cells in patients with pathological hyperprolactinemia
R Gerli, P Rambotti, I Nicoletti, S Orlandi, G Migliorati, C Riccardi
Clinical & Experimental Immunology 1986
FOLLOW-UP OF PROLACTIN LEVELS IN LONG-TERM OESTROGEN-TREATED MALE-TO-FEMALE TRANSSEXUALS WITH REGARD TO PROLACTINOMA INDUCTION
LJ Gooren, W Harmsen-Louman, H Kessel
Clinical Endocrinology 1985
LONG-TERM BROMOCRIPTINE THERAPY MAY RESTORE THE INHIBITORY CONTROL OF PROLACTIN RELEASE IN SOME PATIENTS WITH PATHOLOGICAL HYPERPROLACTINEMIA
KY Ho, GA Smythe, PJ Compton, L Lazarus
Australian and New Zealand Journal of Medicine 1985
Decreased tuberoinfundibular and pituitary dopamine and dihydroxyphenylacetic acid concentrations in rats with estrogen-induced pituitary tumors
TD Paolo, M Daigle, N Barden
Neuroscience Letters 1985
Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients
LD Marinis, A Mancini, S Minnielli, R Masala, C Anile, G Maira, A Barbarino
Metabolism 1985
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma
EC Uberti, G Trasforini, S Salvadori, A Margutti, C Rotola, M Bianconi, V Teodori, R Tomatis, R Pansini
Metabolism 1985
Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas
D Tallo, WB Malarkey
American Journal of Obstetrics and Gynecology 1985
Evaluation of hypothalamic dopaminergic function by neuropharmacologic means in aged women
D Cocchi, C Castoldi, S Locatelli, A Novelli, AM Colombo, A Tammaro, EE Mller
Journal of Neural Transmission 1985
Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man
R Caldara, C Barbieri, V Piepoli, M Borzio, E Masci
Gut 1985
Contemporary Endocrinology
SH Ingbar
1985
Neuroendocrine Perspectives
SR Ojeda, SS (White), HF Urbanski, LI Aguado
Neuroendocrine Perspectives 1984
Prolactin Secretion: a Multidisciplinary Approach
ME Molitch, S Reichlin
Prolactin Secretion: a Multidisciplinary Approach 1984
Mechanisms involved in the prolactin-releasing effect of benserazide
EA Parati, A Penalva, GP Bondiolotti, M Parenti, V Locatelli, GB Picotti, D Cocchi, EE Müller
European Journal of Pharmacology 1984
Psychoneuroendocrine Dysfunction
NS Shah, AG Donald
1984
Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics
AE Pontiroli, L Falsetti
BMJ : British Medical Journal 1984
Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man
JI Nurnberger, S Simmons-Alling, L Kessler, S Jimerson, J Schreiber, E Hollander, CA Tamminga, NS Nadi, DS Goldstein, ES Gershon
Psychopharmacology 1984
Peptides, Hormones, and Behavior
CB Nemeroff, AJ Dunn
1984
RECIPROCAL PATTERN OF THE TSH AND PRL RESPONSES TO DOPAMINE RECEPTOR BLOCKADE IN WOMEN WITH PHYSIOLOGICAL OR PATHOLOGICAL HYPERPROLACTINAEMIA
F Massara, F Camanni, M Martra, GC Dolfin, EE Müller, GM Molinatti
Clinical Endocrinology 1983
THE INTERRELATIONSHIPS BETWEEN PROLACTIN AND THYROTROPHIN SECRETION FOLLOWING DOPAMINERGIC BLOCKAGE IN PATIENTS WITH MILD HYPERPROLACTINAEMIA WITHOUT ANY DEMONSTRABLE PITUITARY TUMOUR
JM Spitz, M Haas, S Trestian, E Zylber-Haran, S Shilo
Clinical Endocrinology 1983
Investigation of hypothalamic-pituitary disease
RP Lamberton, IM Jackson
Clinics in Endocrinology and Metabolism 1983
TSH neuroregulation and alterations in disease states
JR Peters, SM Foord, C Dieguez, MF Scanlon
Clinics in Endocrinology and Metabolism 1983
The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone
S Nicosia, D Oliva, G Giannattasio, A Spada
Journal of Endocrinological Investigation 1983
Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas
F Iannotta, P Fachinetti, A Fachinetti, G Pinotti, L Usellini
Journal of Endocrinological Investigation 1983
Neuroendocrinology of Aging
J Meites
1983
Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications:
EE Müller, V Locatelli, S Cella, A Peñalva, A Novelli, D Cocchi
Drugs 1983
PROLACTIN STIMULATION BY INTRAVENOUS LABETALOL IS MEDIATED INSIDE THE CENTRAL NERVOUS SYSTEM
C Barbieri, MT Larovere, G Mariotti, C Ferrari, R Caldara
Clinical Endocrinology 1982
PULSATILE GONADOTROPHIN SECRETION IN HYPERPROLACTINAEMIC AMENORRHOEA AND THE RESPONSE TO BROMOCRIPTINE THERAPY
PJ Moult, LH Rees, GM Besser
Clinical Endocrinology 1982
Effects of L-dopa on plasma levels of parathyroid hormone in calves
J Blum, D Schams, W Born, MD Prada
Journal of Endocrinological Investigation 1982
Long term bromocriptine therapy in Cushing’s disease
LP Kapcala, IM Jackson
Journal of Endocrinological Investigation 1982
Nomifensine-induced pregnancy in a hyperprolactinemic woman
AR Genazzani, VD Leo, F Camanni, EE Müller
Journal of Endocrinological Investigation 1982
Impaired prolactin responsiveness to dopamine antagonists in acromegaly
F Camanni, F Massara, M Santià, GM Molinatti, EE Müller
Metabolism 1982
Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery
A Barbarino, LD Marinis, C Anile, E Menini, G Merlini, G Maira
Metabolism 1982
Damage to Hypothalamic Dopaminergic Neurons Is Associated with Development of Prolactin-Secreting Pituitary Tumors
DK Sarkar, PE Gottschall, J Meites
Science 1982
ALTERED DOPAMINERGIC REGULATION OF THYROTROPHIN RELEASE IN PATIENTS WITH PROLACTINOMAS: COMPARISON WITH OTHER TESTS OF HYPOTHALAMIC-PITUITARY FUNCTION
MF Scanlon, MD Rodriguez-Arnao, AM McGREGOR, D Weightman, M Lewis, DB Cook, A Gomez-Pan, R Hall
Clinical Endocrinology 1981
Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients
S Bansal, LA Lee, PD Woolf
The American Journal of Medicine 1981
A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human
JD Veldhuis, TJ Worgul, R Monsaert, JM Hammond
Journal of Endocrinological Investigation 1981
Effects of increased central dopaminergic tonus on gonadotropin secretion
P Travaglini, C Montanari, M Ballabio, R Elli, RC Scaperrotta, G Faglia
Journal of Endocrinological Investigation 1981
Dopamine-mimetic and antagonist drugs: Diagnostic and therapeutic applications in endocrine disorders
EE Müller, F Camanni, AR Genazzani, F Casanueva, D Cocchi, V Locatelli, F Massara, P Mantegazza
Life Sciences 1981
Validity of hypothalamic-pituitary testing in hyperprolactinemia: Prolactin responses to insulin hypoglycemia and arginine
DF Archer, JH Harger, EE Moore, LJ Hough
American Journal of Obstetrics and Gynecology 1981
Tests of Prolactin Secretion in the Diagnosis of Hyperprolactinemic States: Nomifensine and Domperidone**Supported by grants from Project “Biology and Reproduction,” Consiglio Nationale delle Ricerche (C.N.R.), Rome (to A. R. G. and E. E. Müller)
F Massara, AR Genazzani, F Camanni, VD Leo, GM Molinatti, EE Müller
Fertility and Sterility 1981
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease
A Martinez-Campos, P Giovannini, E Parati, A Novelli, T Caraceni, E Muller
Journal of neurology, neurosurgery, and psychiatry 1981
Neuroendocrine Regulation and Altered Behaviour
PD Hrdina, RL Singhal
1981
EFFECT OF DOPAMINE INFUSION ON SERUM PROLACTIN CONCENTRATION IN NORMAL AND HYPERPROLACTINAEMIC SUBJECTS
E Reschini, C Ferrari, M Peracchi, R Fadini, M Meschia, PG Crosignani
Clinical Endocrinology 1980
Diminished prolactin reserve in acromegaly
IM Spitz, D Barzilai, R Luboshitzky
Metabolism 1980
Prolactin-secreting pituitary adenomas: Serum and tissue prolactin levels with ultrastructural correlation
DF Archer, H Salazar, JC Maroon, LJ Hough
American Journal of Obstetrics and Gynecology 1980
The Pituitary Adenoma
KD Post, IM Jackson, S Reichlin
1980
Trends in the management of prolactinomas.
British medical journal 1980
Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin
MF Scanlon, M Pourmand, AM McGregor, MD Rodriguez-Arnao, K Hall, A Gomez-Pan, R Hall
Journal of Endocrinological Investigation 1979
Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients
RC Smith, CA Tamminga, JW Crayton, H Dekirmenjian, JM Davis
Psychopharmacology 1979
Clinical Neuroendocrinology
CR Edwards
Clinical Neuroendocrinology 1977

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts